Generation of a monoclonal antibody reactive to prefusion myocytes by Kurisaki, Tomohiro et al.
ORIGINAL PAPER
Generation of a monoclonal antibody reactive to prefusion
myocytes
Tomohiro Kurisaki • Aki Masuda • Shiho Nakagiri •
Yoshihiro Hayata • Motoki Kuhara •
Yoshiro Kishi • Atsuko Sehara-Fujisawa
Received: 7 March 2011/Accepted: 26 April 2011/Published online: 20 May 2011
 The Author(s) 2011. This article is published with open access at Springerlink.com
Abstract We established a novel monoclonal antibody,
Yaksa that is speciﬁc to a subpopulation of myogenic cells.
The Yaksa antigen is not expressed on the surface of
growing myoblasts but only on a subpopulation of myog-
enin-positive myocytes. When Yaksa antigen-positive
mononucleated cells were freshly prepared from a murine
myogenic cell by a cell sorter, they fused with each other
and formed multinucleated myotubes shortly after replating
while Yaksa antigen-negative cells scarcely generated
myotubes. These results suggest that Yaksa could segregate
fusion-competent, mononucleated cells from fusion–
incompetent cells during muscle differentiation. The Yaksa
antigen was also expressed in developing muscle and
regenerating muscle in vivo and it was localized at sites of
cell–cell contact between mono-nucleated muscle cells and
between mono-nucleated muscle cells and myotubes. Thus,
Yaksa that marks prefusion myocytes before myotube
formation can be a useful tool to elucidate the cellular and
molecular mechanisms of myogenic cell fusion.
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Introduction
Myoblast fusion is essential to form the multi-nucleated
muscle ﬁbers that provide the contractile strength of
skeletal muscle (Buckingham 2001; Buckingham 2006;
Horsley and Pavlath 2004). It is also responsible for the
postnatal maintenance, growth, repair, and regeneration of
skeletal muscles (Cerletti et al. 2008; Rudnicki et al. 2008).
Myoblast fusion follows an ordered set of events: recog-
nition, adhesion, and plasma membrane union, which
results in syncytium formation (Jansen and Pavlath 2008).
During the last decade, intensive study using model ani-
mals including Drosophila, Zebraﬁsh, chick, and mouse
have yielded many insights into the fusion mechanism of
myoblasts (Haralalka and Abmayr 2010; Moore et al. 2007;
Rochlin et al. 2010; Mermelstein et al. 2005). It is also
suggested that several of the signaling cascades involved in
myoblast fusion are evolutionarily conserved (Buckingham
2001; Krauss 2010). However, relatively little is yet known
about the molecular mechanism of membrane union.
Myogenic cell lines have been useful model systems for
the study of muscle differentiation and cellular fusion. The
murine myoblast C2 is a well-characterized myogenic cell
line (Yaffe and Saxel 1977). Serum deprivation triggers a
series of events that result in myogenic differentiation in
C2 cells. Expression of myogenin (mg), a transcription
factor critical for myotube formation, is the earliest event
(Andres and Walsh 1996). After that, the cells withdraw
from the cell cycle, followed by cellular fusion resulting in
the formation of multinucleated myotubes (Halevy et al.
1995; Miller 1990; Parker et al. 1995). Only a fraction of
C2 myoblasts undergo terminal differentiation upon serum
deprivation, while others, known as reserve cells, do not
follow the cellular events described above (Morgan and
Partridge 2003; Yoshida et al. 1998).
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relatively long period of several days. This means that
only a small population of fusion-competent cells exists at
any speciﬁc point in time during differentiation, making
elucidation of the cellular and molecular mechanisms of
myogenic cell fusion difﬁcult. Antibody (Ab) that rec-
ognize fusion-competent cells alive before myotube for-
mation, is one of the powerful tools, but not available so
far. Here we report successful isolation of fusion-com-
petent myocytes with a novel monoclonal antibody,
Yaksa.
Materials and methods
Materials
Chemicals were purchased from Sigma (St. Louis, MO,
USA) and Nacalai Tesque (Kyoto, Japan). Reagents for
molecular biology were purchased from TaKaRa (Kyoto,
Japan) and Toyobo (Osaka, Japan) unless otherwise indi-
cated. DAPI, Hoechst 33342, Fluorochrome-conjugated
Streptavidin (StAv) were purchased from Molecular Probes
(Eugene, OR, USA).
Antibodies
The antibodies used and their sources were as follows.
ALEXA488-conjugated goat anti-rat IgG which have been
adsorbed against mouse IgG and mouse serum, was from
Molecular Probes. Isotype-matched control IgG2a and
IgG2a-bio, were from BD Pharmingen (San Diego, CA,
USA). Anti-myogenin mAb (F5D) was from Santa Cruz
(Santa Cruz, CA, USA). Anti-alpha actinin mAb (EA-53)
was from Sigma. Anti-desmin (D9) was from Progen
(Heidelberg, Germany). Cy3-conjugated goat anti-mouse
IgG was from Amersham (Bucks, UK). Biotinylation of
immunoglobulin was performed by using EZ-Link Sulfo
NHS-LC-Biotin (Pierce, Rockford, IL, USA) according to
the manufacturer’s instructions.
Animals
Mice (C57BL6/J) and Wistar rats were purchased from
Shimizu Laboratory Supplies (Kyoto, Japan) and main-
tained under speciﬁc pathogen-free conditions in environ-
mentally controlled clean rooms at the Institute for Frontier
Medical Sciences, Kyoto University. The experiments were
conducted according to institutional ethical guidelines for
animal experimentation and safety guidelines for gene
manipulation experiments.
Cell culture
A subclone of C2 myoblasts, designated C2/4 (Yoshida
et al. 1996), was used and is referred to simply as C2 in this
study. The cells were routinely propagated in the growth
medium, DMEM supplemented with 10% fetal calf serum
(FCS), on collagen type I-coated culture plates (Iwaki,
Japan). To induce differentiation, cells were seeded at a
density of 2.5 9 10
4 cells/well (12-well plates) or the
equivalent in growth medium, and 24 h later switched to
the differentiation medium, DMEM supplemented with 2%
horse serum (HS). Myotube formation was observed 72 h
after the medium change. Primary myoblasts (pMB) were
prepared from the gastrocnemius muscle of an 8-week-old
mouse as described before (Hashimoto et al. 2004; Wada
et al. 2002).
Stable transformant
mgEGFP-C2, the stable transformant used in this study,
was generated using a pMG-dEGFP vector. The pMG-
dEGFP vector was generated by replacing the CMV pro-
moter region of pd4EGFP-N1 (Clontech, Mountain View,
CA, USA) with the upstream region of the myogenin gene
(Fujisawa-Sehara et al. 1993). Transfections were per-
formed using Lipofectamine PLUS (Invitrogen) according
to the manufacturer’s instructions. C2 cells were ﬁrst
transfected with pMG-dEGFP and selected by Geneticin
(400 lg/ml, Invitrogen) to isolate several clones.
Establishment of monoclonal antibodies
A four-week-old female Wistar rat was immunized with
GFP-expressing mgEGFP-C2 by using a differential foot-
pad immunization protocol (Dzionek et al. 2000). Mono-
clonal antibodies (Abs) were established according to a
standard procedure (Harlow and Lane 1988). The strategies
for monoclonal antibody (mAb) selection are described in
the ‘‘Results’’ section. Isotyping was performed using a Rat
Monoclonal Antibody Isotyping Test Kit (Serotec, Oxford,
UK) according to the manufacturer’s instructions.
Flow cytometry and cell sorting
For ﬂow cytometry, cells were dispersed with Accutase
(Innovative Cell Technology, San Diego, CA, USA),
stained and then analyzed using a FACScan analyzer and
CellQuest software (BD, Mountain View, CA, USA). Dead
cells were excluded from the plots based on propidium
iodide staining. mgEGFP-C2 cells for immunization and
Yaksa antibody-reactive cells were fractionated on a FACS
Vantage or FACSAria cell sorter (BD).
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Thirty-six hours after induction of differentiation, mAb-
reactive cells were positively selected from C2 cells with
biotinylated Yaksa mAb using either a FACS Vantage or
IMagnet cell sorter. Yaksa antigen-negative cells were
collected from the negatively selected fraction. Sorted cells
were plated at 2 9 10
5 cells/well in 24-well plates, cul-
tured for 6–18 h, and examined by microscopy.
Regeneration of muscle
To induce muscle regeneration, 50–100 ll of cardiotoxin
(CTX; 10 lM in saline, Wako Chemicals) was injected
into the muscle of 8-week-old mice. Regenerating muscle-
derived mononucleated cells were prepared from C57BL/6
mice as previously described (Ojima et al. 2004).
Immunostaining
For immunostaining, PFA-ﬁxed and permeabilized cells or
unﬁxed cells were stained. Unﬁxed or PFA-ﬁxed mouse
embryos were cryosectioned, dried, and stained with
hybridoma supernatant or antibodies. Tibialis anterior (TA)
muscle was frozen in isopentane cooled with liquid
nitrogen.
Results
Imaging expression of myogenin in live C2 cells
To generate monoclonal antibodies (mAb) reactive to
prefusion myocytes, we used C2 cells expressing myogenin
as the immunogen. Myogenic cells acquire fusion compe-
tence only after the expression of myogenin, a muscle
speciﬁc transcription factor that is essential for the devel-
opment of skeletal muscle (Nabeshima et al. 1993). Only a
fraction of C2 myoblasts express myogenin and undergo
terminal differentiation after induction. Thus, enrichment
of myogenin-expressing cells before fusion should enable
efﬁcient generation of monoclonal antibodies against pre-
fusion myocytes. Then, we generated the cell line to
visualize myogenin-expressing cells in living C2 cells. We
previously showed that the region spanning 4 kb upstream
of the myogenin gene is sufﬁcient to mimic expression of
myogenin mRNA during development (Fujisawa-Sehara
et al. 1993). C2 cells were transiently transfected with
pMG-dEGFP, a plasmid in which expression of destabi-
lized GFP was driven by the 4 kb regulatory region of the
myogenin gene, and stable transformants were established
according to the following criteria. First, GFP is unde-
tectable when cultured in growth medium. Second, GFP is
activated after induction of differentiation. Third, the
expression proﬁle of GFP correlates with that of endoge-
nous myogenin. mgEGFP-C2, was one of the stable
transformants that satisﬁed those criteria. mgEGFP-C2
formed myotubes after induction of differentiation similar
to the original C2 cells (data not shown).
As shown in Fig. 1, immunoﬂuorescent staining reveals
that neither GFP nor myogenin is expressed in growing
mgEGFP-C2 and that GFP-positive cells also express
myogenin at 48 h after myogenic induction. As determined
by immunoﬂuorescent staining, 10–20% of mgEGFP-C2
cells express myogenin at 12–48 h after induction, and
more than 85% of myogenin-positive cells express GFP at
these time points. GFP-positive/myogenin-negative cells
were hardly detectable (Fig. 1, data not shown). Therefore,
we assumed that the expression of EGFP correlated with
that of myogenin in mgEGFP-C2 cells at 12–48 h after
induction. Then we generated rat monoclonal antibodies by
Fig. 1 High correlation between GFP and myogenin expression in
mgEGFP-C2. mgEGFP-C2 culture at 2 days after induction of
differentiation (A–D), and in 10%CS-DMEM (E–H) was stained.
A, E: phase contrast; B, F: anti-myogenin staining; C, G: GFP; D, H:
DAPI staining
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123differential footpad immunization with mgEGFP-C2 as
described in ‘‘Materials and Methods’’.
Screening of monoclonal antibodies that detect
fusion-competent myocytes
We screened almost 300 mAbs under the following criteria
(Fig. 2). First, mAbs against prefusion myocytes react with
a part of C2 cells after induction because only a subpop-
ulation of C2 cells commit themselves to fusion-competent
cells. Second, mAbs against prefusion myocytes enable
efﬁcient isolation of prefusion myocytes. If most of the
cells sorted out with a mAb form myotubes, we assumed
that the mAb reacted with prefusion myocytes. Last, the
mAbs also react with embryonic muscle on the assumption
that embryonic muscle and muscle satellite cells essentially
share the same molecular machinery for myotube forma-
tion. Finally, we established eight mAbs that satisﬁed the
above criteria. Yaksa was one of them. Yaksa refer to
the nature-spirit among eight guardians for Buddhism. The
isotype of Yaksa was IgG2a. The ﬂow cytometric proﬁle
showed that Yaksa did not react with undifferentiated C2
cells and did react with only 20–30% of differentiating
C2 cells (Fig. 3A). To characterize Yaksa-positive cells,
C2 cells after myogenic induction for 1.5 days (36 h), were
double-stained with anti-myogenin Ab and Yaksa and
analyzed using a FACScan. As shown in Fig. 3B, a sub-
population of myogenin-positive myocytes were Yaksa-
positive cells. When we performed a replating assay as
described in ‘‘Materials and methods’’, most of the Yaksa-
positive cells formed myotubes 6–8 h after replating
(Fig. 3C, S1) while Yaksa antigen (Ag)-negative cells and
unsorted cells had formed only a few myotubes at the same
time point. This indicates that Yaksa either recognize or
isolate a subpopulation of cells that fuse with one another
synchronously out of heterogeneously differentiating cell
culture. Neither Yaksa Ag-negative cells nor unsorted cells
formed more than a few myotubes even 36 h after replat-
ing. This suggests that Yaksa recognize fusion competency,
not developmental delay, in this replating assay, and we
concluded that Yaksa is a monoclonal Ab reactive to
prefusion myocytes.
Yaksa antigen expression in vivo
Next, we investigated the expression proﬁle of Yaksa Ag in
vivo. Yaksa Ag was expressed in trunk at embryonic day
(E) 13.5 (Fig. 4A). Yaksa stained tissue was also coun-
terstained with anti-desmin Ab (Fig. 4B) and anti-myosin
heavy chain Ab (data not shown). Then we concluded that
Yaksa Ag was expressed in developing muscle. Yaksa Ag
was also expressed in regenerating muscles (Fig. 4D–F).
The tibialis anterior (TA) muscles were experimentally
damaged by cardiotoxin (CTX) injection to induce muscle
regeneration (Hirata et al. 2003). The number of mono-
nucleated cells in injured areas increased signiﬁcantly
following CTX injection, with a peak around day 3. The
increase in cell number around day 3 is mainly attributable
to proliferation of myogenic cells. Regenerating myotubes
with central nuclei started to appear at day 3 and became
more evident at days 5–7 post-injection. As shown in
Fig. 4D–F and Fig. S2, Yaksa Ag was expressed in the
plasma membrane of developing myotubes at days 3–5
after CTX injection. We did not detect Yaksa at days 0–2
and days 6–7 (Fig. S2, data not shown). These data suggest
that Yaksa was expressed on fusing cells. Yaksa-positive
cells were found in single-cell suspensions prepared from
Fig. 2 Screening procedure. Mononucleated cell suspension was
prepared from either growing or differentiated C2, stained with mAbs
generated from rat immunized with myogenin-positive cells, and
sorted. Staining pattern was categorized to three groups: No stained,
All stained, and Some stained. We selected a mAb which does not
stain growing C2 but some C2 cells after differentiation (red boxed).
Then if the cells reactive with a mAb form myotubes efﬁciently by a
replating assay (red boxed), we assumed that the mAb reacted with
prefusion myocytes. For details, see ‘‘Materials and methods’’, and
‘‘Results’’
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We also conﬁrmed Yaksa Ag expression in primary myo-
blasts prepared from adult mouse (Fig. 4H). The culture
apparently contained two cell types, that is Yaksa-positive/
high cells and Yaksa-negative/low cells. We presumed that
the prepared primary myoblast culture contained prefusion
myocytes already. As in the case of C2 cells, the amount of
Yaksa Ag expression in individual cells correlated with
their fusion competence. Primary myoblasts highly
expressing Yaksa Ag fused with each other as early as 3 h
after replating, much earlier than Yaksa-low myoblasts
(data not shown). Yaksa did not react with several non-
myogenic cell lines including osteoclast-precursor cell
lines, ﬁbroblasts, hematopoietic cells, and ES cells (data
not shown).
Yaksa localization on fusing myoblasts
To determine the localization of Yaksa Ag, pMB was
transduced using a retrovirus vector carrying GFP to
visualize the shape of the cell and stained with Yaksa. As
shown in Fig. 4I–L and Fig. S3, Yaksa Ag localized at sites
of cell–cell and cell-myotube contact. We did not detect
this signal when using the isotype-matched control IgG2a
(Fig. S3).
Discussion
We established a novel monoclonal antibody, Yaksa that
speciﬁcallyrecognizesprefusionmyocytes.Yaksa providesa
noveltooltoclarifythemolecularmechanismsofmusclecell
fusion, because this antibody can mark or isolate prefusion
myocytes among heterogeneously differentiating myoblasts.
So far, several surface markers for differentiating
myoblasts have been reported including N-CAM and
M-cadherin (Blanco-Bose et al. 2001; Capkovic et al.
2008; Charrasse et al. 2007). However, either M-cadherin
or NCAM, for example, is expressed on entire population
of C2 cells after induction and neither marks a subpopu-
lation of fusogenic C2 cells (data not shown). To our
knowledge, a monoclonal antibody with which prefusion
myocytes in mammal are sorted out alive, has not been
reported yet although antiserum named as anti-M-24 was
reported to react with prefusion myocytes in chick embryos
30 years ago (Friedlander and Fischman 1977).
Fig. 3 Characterization of Yaksa. A FACScan analysis of Yaksa
antigen on C2 cells. Upper growing, middle just before induction,
lower 1.5 days after induction, dashed line control IgG2a. B Subpop-
ulation of myogenin-positive cells express Yaksa antigen. FL1:
myogenin stained with Alexa488, FL2; Yaksa antigen stained with
PE. Thirty-six hours after induction, C2 cells were stained with
control IgG (Upper Left), anti mg Ab (Lower Left), Yaksa (Upper
Right), and anti mg Ab and Yaksa (Lower Right). C Yaksa-positive
cells form multinucleated cells shortly after replating. Thirty-six
hours after induction, C2 cells sorted with Yaksa were replated,
cultured for 6 h, and then stained with anti-alpha actinin (green) and
DAPI (red). Yaksa-positive cells form binuclear or multinucleated
cells shortly after replating
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implications for the fusion competence of cultured prefu-
sion myocytes. First, most of Yaksa-positive cells fused
with each other shortly after replating while Yaksa-nega-
tive cells scarcely generated multinucleated myotubes,
suggesting that prefusion myocytes fuse among each other
or with multinucleated myotubes. Second, C2 cells gener-
ate prefusion myocytes much earlier before myotube
formation. In this paper, most replating assays were per-
formed at 36 h after induction. However, Yaksa positive-
cells already existed as a small population (2–5%) 24 h
after induction, and they fused with each other within
6–8 h after replating (data not shown). This suggests that
prefusion myocytes in cultured C2 cells could not contact
each other efﬁciently resulting in failure of fusion, despite
their fusion competency.
Fig. 4 Yaksa antigen was
expressed in vivo.
A–C Transverse section of
mouse embryo (E13.5) triple-
stained with Yaksa (A), anti-
Desmin (B) and DAPI (C).
A dorsal quarter of embryo was
shown. Arrow heads Desmin
positive developing muscle.
Signal in the peripheral of
section is non-speciﬁc staining.
D–F Transverse section of
regenerating TA muscle 4 days
after CTX injection was stained
with Yaksa (green, E) and
DAPI (red, F). G FACScan
analysis of single cells prepared
from regenerating TA muscle
3 days after CTX injection.
Cells were stained with Yaksa
(solid) or IgG2a (line).
H FACScan analysis of primary
myoblasts prepared from
gastrocnemius muscle. Cells
were stained with Yaksa (solid)
or IgG2a (line). I–L Yaksa
antigen is expressed at site of
cell–cell contact. Cultures of
pMB expressing GFP (green,
K) were ﬁxed and stained with
biotinylated Yaksa & StAv-
ALEXA594 (red, J) and
Hoechst (blue, L). Arrowheads
Accumulation of Yaksa antigen
at sites of cell–cell contact
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Ag is not identiﬁed yet, speciﬁc expression of Yaksa Ag on
prefusion myocytes and localization at sites of cell–cell
contact imply that Yaksa antigen plays positive roles in
muscle differentiation and membrane fusion. In Drosoph-
ila, it was reported that a multiprotein complex, which was
named FuRMAS (Fusion-Restricted Myogenic-Adhesive
Structure), is assembled at the cell–cell contact site during
fusion (Onel and Renkawitz-Pohl 2009; Kesper et al.
2007). FuRMAS consists of a ring structure of cell adhe-
sion molecules, signaling proteins, and F-actin, and it has
been proposed that FuRMAS serves as a signaling center,
restricts the area of membrane fusion, and possibly triggers
membrane breakdown, which leads to cellular fusion.
Moreover, rafts, cholesterol-rich microdomains, likely play
speciﬁc roles in cell fusion (Mukai et al. 2009). Although
FuRMAS in mammalian myoblasts has not been reported
yet, Yaksa would be a useful tool to clarify the molecular
mechanisms of muscle cell fusion including identiﬁcation
of FuRMAS-related complexes in fusing cells. Identiﬁca-
tion of or molecules complexed with Yaksa Ag could be an
alternative way to tackle the mechanisms of muscle cell
fusion.
Acknowledgments This work was supported in part by a Grant-in-
Aid for Scientiﬁc Research on Priority Areas and the project for
realization of regenerative medicine from the Ministry of Education,
Culture, Sports, Science and Technology, and in part by a research
grant for Nervous and Mental Disorders from the Ministry of Health,
Labour and Welfare.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
Andres V, Walsh K (1996) Myogenin expression, cell cycle
withdrawal, and phenotypic differentiation are temporally sep-
arable events that precede cell fusion upon myogenesis. J Cell
Biol 132:657–666
Blanco-Bose WE, Yao CC, Kramer RH, Blau HM (2001) Puriﬁcation
of mouse primary myoblasts based on alpha 7 integrin expres-
sion. Exp Cell Res 265:212–220
Buckingham M (2001) Skeletal muscle formation in vertebrates. Curr
Opin Genet Dev 11:440–448
Buckingham M (2006) Myogenic progenitor cells and skeletal
myogenesis in vertebrates. Curr Opin Genet Dev 16:525–532
Capkovic KL, Stevenson S, Johnson MC, Thelen JJ, Cornelison DD
(2008) Neural cell adhesion molecule (NCAM) marks adult
myogenic cells committed to differentiation. Exp Cell Res
314:1553–1565
Cerletti M, Shadrach JL, Jurga S, Sherwood R, Wagers AJ (2008)
Regulation and function of skeletal muscle stem cells. Cold
Spring Harb Symp Quant Biol 73:317–322
Charrasse S, Comunale F, Fortier M, Portales-Casamar E, Debant A,
Gauthier-Rouviere C (2007) M-cadherin activates Rac1 GTPase
through the Rho-GEF trio during myoblast fusion. Mol Biol Cell
18:1734–1743
Dzionek A, Fuchs A, Schmidt P, Cremer S, Zysk M, Miltenyi S, Buck
DW, Schmitz J (2000) BDCA-2, BDCA-3, and BDCA-4: three
markers for distinct subsets of dendritic cells in human
peripheral blood. J Immunol 165:6037–6046
Friedlander M, Fischman DA (1977) Surface antigens of the
embryonic chick myoblast: expression on freshly trypsinized
cells. J Supramol Struct 7:323–338
Fujisawa-Sehara A, Hanaoka K, Hayasaka M, Hiromasa-Yagami T,
Nabeshima Y (1993) Upstream region of the myogenin gene
confers transcriptional activation in muscle cell lineages during
mouse embryogenesis. Biochem Biophys Re Commun 191:
351–356
Halevy O, Novitch BG, Spicer DB, Skapek SX, Rhee J, Hannon GJ,
Beach D, Lassar AB (1995) Correlation of terminal cell cycle
arrest of skeletal muscle with induction of p21 by MyoD.
Science 267:1018–1021
Haralalka S, Abmayr SM (2010) Myoblast fusion in Drosophila. Exp
Cell Res 316:3007–3013
Harlow E, Lane D (1988) Antibodies: a laboratory manual. Cold
Spring Harbor, New York
Hashimoto N, Murase T, Kondo S, Okuda A, Inagawa-Ogashiwa M
(2004) Muscle reconstitution by muscle satellite cell descendants
with stem cell-like properties. Development 131:5481–5490
Hirata A, Masuda S, Tamura T, Kai K, Ojima K, Fukase A,
Motoyoshi K, Kamakura K, Miyagoe-Suzuki Y, Takeda S
(2003) Expression proﬁling of cytokines and related genes in
regenerating skeletal muscle after cardiotoxin injection: a role
for osteopontin. Am J Pathol 163:203–215
Horsley V, Pavlath GK (2004) Forming a multinucleated cell:
molecules that regulate myoblast fusion. Cells Tissues Organs
176:67–78
Jansen KM, Pavlath GK (2008) Molecular control of mammalian
myoblast fusion. Methods Mol Biol 475:115–133
Kesper DA, Stute C, Buttgereit D, Kreiskother N, Vishnu S,
Fischbach KF, Renkawitz-Pohl R (2007) Myoblast fusion in
Drosophila melanogaster is mediated through a fusion-restricted
myogenic-adhesive structure (FuRMAS). Dev Dyn 236:404–415
Krauss RS (2010) Regulation of promyogenic signal transduction by
cell–cell contact and adhesion. Exp Cell Res 316:3042–3049
Mermelstein CS, Portilho DM, Medeiros RB, Matos AR, Einicker-
Lamas M, Tortelote GG, Vieyra A, Costa ML (2005) Cholesterol
depletion by methyl-b-cyclodextrin enhances myoblast fusion
and induces the formation of myotubes with disorganized nuclei.
Cell Tissue Res 319:289–297
Miller JB (1990) Myogenic programs of mouse muscle cell lines:
expression of myosin heavy chain isoforms, MyoD1, and
myogenin. J Cell Biol 111:1149–1159
Moore CA, Parkin CA, Bidet Y, Ingham PW (2007) A role for the
Myoblast city homologues Dock1 and Dock5 and the adaptor
proteins Crk and Crk-like in zebraﬁsh myoblast fusion. Devel-
opment 134:3145–3153
Morgan JE, Partridge TA (2003) Muscle satellite cells. Int J Biochem
Cell Biol 35:1151–1156
Mukai A, Kurisaki T, Sato SB, Kobayashi T, Kondoh G, Hashimoto
N (2009) Dynamic clustering and dispersion of lipid rafts
contribute to fusion competence of myogenic cells. Exp Cell Res
315:3052–3063
Nabeshima Y, Hanaoka K, Hayasaka M, Esumi E, Li S, Nonaka I
(1993) Myogenin gene disruption results in perinatal lethality
because of severe muscle defect. Nature 364:532–535
Ojima K, Uezumi A, Miyoshi H, Masuda S, Morita Y, Fukase A,
Hattori A, Nakauchi H, Miyagoe-Suzuki Y, Takeda S (2004)
J Muscle Res Cell Motil (2011) 32:31–38 37
123Mac-1(low) early myeloid cells in the bone marrow-derived SP
fraction migrate into injured skeletal muscle and participate in
muscle regeneration. Biochem Biophys Re Commun 321:
1050–1061
Onel SF, Renkawitz-Pohl R (2009) FuRMAS: triggering myoblast
fusion in Drosophila. Dev Dyn 238:1513–1525
Parker SB, Eichele G, Zhang P, Rawls A, Sands AT, Bradley A,
Olson EN, Harper JW, Elledge SJ (1995) p53-Independent
expression of p21Cip1 in muscle and other terminally differen-
tiating cells. Science 267:1024–1027
Rochlin K, Yu S, Roy S, Baylies MK, Richardson BE (2010)
Myoblast fusion: when it takes more to make one. Dev Biol
341:66–83
Rudnicki MA, Le Grand F, McKinnell I, Kuang S (2008) The
molecular regulation of muscle stem cell function. Old Spring
Harb Symp Quant Biol 73:323–331
Wada MR, Inagawa-Ogashiwa M, Shimizu S, Yasumoto S, Hashim-
oto N (2002) Generation of different fates from multipotent
muscle stem cells. Development 129:2987–2995
Yaffe D, Saxel O (1977) Serial passaging and differentiation of
myogenic cells isolated from dystrophic mouse muscle. Nature
270:725–727
Yoshida S, Fujisawa-Sehara A, Taki T, Arai K, Nabeshima Y (1996)
Lysophosphatidic acid and bFGF control different modes in
proliferating myoblasts. J Cell Biol 132:181–193
Yoshida N, Yoshida S, Koishi K, Masuda K, Nabeshima Y (1998)
Cell heterogeneity upon myogenic differentiation: down-regula-
tion of MyoD and Myf-5 generates ‘reserve cells’’. J Cell Sci
111:769–779
38 J Muscle Res Cell Motil (2011) 32:31–38
123